|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11,338 GBX | +0.78% |
|
+4.30% | +7.04% |
June 8 (Reuters) - The U.S. Food and Drug Administration advisers on Thursday backed the use of Sanofi and partner AstraZeneca's experimental antibody to prevent respiratory syncytial virus (RSV) infections in infants and children up to two years of age.
(Reporting by Mariam Sunny and Raghav Mahobe in Bengaluru; Editing by Maju Samuel)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 11,342 GBX | +0.82% | +4.30% | 215B | ||
| 88.93 EUR | +0.86% | +2.45% | 117B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +7.04% | 215B | |
| +25.46% | 659B | |
| +25.14% | 557B | |
| -4.86% | 359B | |
| +16.44% | 322B | |
| +8.34% | 297B | |
| +7.00% | 210B | |
| -6.91% | 200B | |
| -8.79% | 149B | |
| -5.59% | 146B |
ASTRAZENECA PLC 
